Skip to main content

Table 2 First line trials of 2 nd generation TKI in EGFR mutated patients

From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

  N OR% mPFS (mo) mOS (mo)
Dacomitinib     
Phase II trial30 92 74 17 NR
Afatinib     
LUX LUNG II trial 34     
All EGFR mutations 129 61 10.1 24.8
Exon 1921 mutations 106 66 13.7 38.7
LUX LUNG III trial 35     
All EGFR mutations     
Afatinib 230 56 11.1 NR
Cis/Gem 115 23 6.9 NR
Exon 1921 mutations     
Afatinib 204 - 13.6 NR
Cis/Gem 104 - 6.9 NR
LUX LUNG VI trial 39     
All EGFR mutations     
Afatinib 242 66.9 11.1  
Cis/Gem 122 23 5.6  
XL647     
Phase II trial53     
All EGFR mutations 41 20 5.3 19
Exon 1921 mutations 14 57 9.3 NR